Who Is Most Likely to Respond to TMS for Depression?

Who is most likely to respond to TMS?

No single characteristic can reliably determine who will respond to transcranial magnetic stimulation (TMS) for depression. Research can identify factors associated with better outcomes across groups, but these TMS success predictors cannot tell an individual patient whether treatment will work for them.

Across studies, people with less extensive treatment resistance often have better average outcomes. Certain symptom patterns, younger age and receiving a sufficient treatment course have also been associated with response in some research. These are tendencies—not rules—and findings vary by TMS protocol, patient population and how response is defined.

TMS does not work for everyone. A psychiatric assessment remains more useful than any single checklist because it considers the diagnosis, previous treatments, current symptoms, medications, other health conditions and personal treatment goals.

Does treatment-resistant depression respond to TMS?

Yes. TMS is commonly considered for appropriately selected people whose depression has not improved sufficiently with antidepressants, psychotherapy or both. Greater treatment resistance may be associated with a lower average probability of response, but it does not mean that TMS cannot help.

The number, adequacy and type of previous treatments matter when clinicians assess treatment resistance. Someone who has had several unsuccessful treatments may still experience a meaningful improvement with TMS. Population-level response rates should not be used to rule an individual in or out without a clinical assessment.

Does age affect TMS response?

Some studies have associated younger age with a greater likelihood of response, but age alone is not a reliable predictor. Older adults can respond to TMS, and outcomes may also be influenced by factors that sometimes accompany aging, such as differences in brain anatomy, medical conditions, medications or the clinical features of depression.

Clinicians therefore consider a person’s overall health and circumstances rather than applying a simple age cut-off. Treatment protocols may also differ, and evidence from one protocol should not automatically be generalized to every form of TMS.

Do symptoms, anxiety or PTSD influence response?

Depression is not identical from one person to another. Some studies suggest that particular symptom profiles may be associated with different outcomes, but no symptom pattern consistently predicts success. Severe symptoms do not automatically mean that TMS will fail.

Co-occurring anxiety may be associated with less improvement in some patient groups, although people with both depression and anxiety can still benefit. PTSD and other psychiatric conditions can affect treatment planning and the interpretation of symptoms. Evidence also depends on which condition is being treated and which TMS protocol is used, so these diagnoses should not be treated as simple yes-or-no predictors.

Do medications affect the likelihood of response?

Many people receive TMS while continuing psychiatric medications. Research has examined whether particular medication classes are associated with better or poorer outcomes, but findings are not consistent enough to predict an individual response based on medication alone.

Current medications remain clinically relevant because they may affect symptoms, tolerability, seizure risk and treatment planning. Patients should not stop or change medication to try to improve their odds of responding to TMS without guidance from their prescriber.

Does the number of TMS sessions matter?

Treatment dose may matter. A 2025 real-world study by Benster and colleagues found that the total number of repetitive TMS sessions was a positive predictor of response, with responders receiving more sessions on average than non-responders.

This is an association, not proof that adding sessions will improve the outcome for every patient. People who continue treatment may differ from those who stop earlier, and there is no single universally optimal number of sessions. Decisions about course length should consider the protocol, progress, tolerability and individual clinical circumstances.

Can a brain scan, EEG or biomarker predict whether TMS will work?

Not reliably in routine clinical care. Researchers are studying magnetic resonance imaging, functional connectivity, electroencephalography (EEG), genetics, blood markers and computerized prediction models. Some findings are promising, but they require further validation and are not established as definitive tests for selecting individual patients.

These tools may eventually help refine treatment selection or target stimulation more precisely. At present, a scan, EEG result or commercial biomarker should not be presented as a guarantee of response.

How do I know if TMS is working?

Clinicians usually track symptoms before and throughout treatment using regular conversations and standardized rating scales. Possible signs of improvement include better mood, interest, energy, concentration, sleep or daily functioning. Changes may be gradual, and different symptoms may improve at different times.

Some people notice improvement relatively early, while others require more of the treatment course before a meaningful change becomes clear. Early improvement can be encouraging, but a lack of immediate change does not by itself prove that treatment will fail. Progress should be reviewed in the context of the protocol, number of sessions received and overall clinical picture.

How can I find out whether TMS is appropriate for me?

The best available predictors provide probabilities, not personal certainty. Determining whether TMS is appropriate requires an individualized psychiatric assessment covering the diagnosis, past treatment trials, current symptoms, medications, comorbidities and treatment goals.

NeuroLinks provides TMS assessment and treatment in Nanaimo for appropriately selected patients from Vancouver Island and elsewhere in British Columbia. If you are considering TMS, you can contact NeuroLinks for information about an assessment without including confidential clinical details in an online message.